Sydney, Nov 07, 2007 (RWE via COMTEX) -- NURPF | charts | news | PowerRating -- (RWE Australian Business News) Neuren Pharmaceuticals Ltd (ASX:NEU) says it has successfully completed the final high-dose Phase 1b safety and tolerability trial for its second lead candidate, NNZ-2566, which is being developed to treat traumatic brain injury (TBI).
